---
title: Fitusiran prophylaxis in people with hemophilia A or B who switched from prior
  BPA/CFC prophylaxis (ATLAS-PPX)
date: '2024-03-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38452197/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240308170616&v=2.18.0.post9+e462414
source: Blood
description: Fitusiran, a subcutaneous (SC) investigational siRNA therapeutic, targets
  antithrombin to rebalance hemostasis in people with hemophilia A or B (PwHA/B),
  irrespective of inhibitor status. This Phase 3, open-label study (NCT03549871) evaluated
  the efficacy and safety of fitusiran prophylaxis in males aged ≥ 12 years with hemophilia
  A or B, with or without inhibitors, who received prior bypassing agent (BPA)/clotting
  factor concentrate (CFC) prophylaxis. Participants continued their prior ...
disable_comments: true
---
Fitusiran, a subcutaneous (SC) investigational siRNA therapeutic, targets antithrombin to rebalance hemostasis in people with hemophilia A or B (PwHA/B), irrespective of inhibitor status. This Phase 3, open-label study (NCT03549871) evaluated the efficacy and safety of fitusiran prophylaxis in males aged ≥ 12 years with hemophilia A or B, with or without inhibitors, who received prior bypassing agent (BPA)/clotting factor concentrate (CFC) prophylaxis. Participants continued their prior ...